Skip to content
MarketScale
‹ Back to IndustriesHealthcare

New Study: Probiotic DE111® Shown to Promote a Healthy Microbiome for Immune Support in Daycare-Attending Children

KENNESAW, GA (December 2, 2020) – Deerland Probiotics and Enzymes has announced the publication of a clinical study showing that the administration of the probiotic Bacillus subtilis DE111® can modify the composition of the microbiome in preschool-aged children. The study, “Daily intake of probiotic strain Bacillus subtilis DE111 supports a healthy microbiome in children attending day-care” published in Beneficial Microbes,…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
New Study: Probiotic DE111® Shown to Promote a Healthy Microbiome for Immune Support in Daycare-Attending Children

KENNESAW, GA (December 2, 2020) – Deerland Probiotics and Enzymes has announced the publication of a clinical study showing that the administration of the probiotic Bacillus subtilis DE111® can modify the composition of the microbiome in preschool-aged children.

The study, “Daily intake of probiotic strain Bacillus subtilis DE111 supports a healthy microbiome in children attending day-care” published in Beneficial Microbes, is an IRB-approved, randomized, double-blind, placebo-controlled four-week trial involving 91 children aged 2 to 6. Results of the study showed that daily consumption of the probiotic strain Bacillus subtilis DE111 positively modulated the gut microbiome profile without changing the overall microbiome equilibrium.

After 8 weeks of daily probiotic consumption, the researchers observed an increase in alpha-diversity at the phylum level, suggesting an expanded functional diversity of the microbiome compared to that of the children in the placebo group. Specifically, there were 9 differentially abundant taxa at the genus level found in the probiotic group, six (of the phylum bacteroidetes) grew in abundance while three (of the phylum firmicutes) were reduced. The six taxa of bacteroidetes that flourished are involved in immune regulation and reduction of inflammation. This modulation of the firmicutes/bacteroidetes ratio of the microbiome in children taking B. subtilis DE111 is a positive indication for healthy gut function.

Overall, according to the researchers, these results suggest B. subtilis DE111 supports the maintenance of a healthy gut through subtle modulations of the microbiome with significant benefits in preschool aged children.

“On the dawn of a new highly modified school year where health takes center stage, this study is highly encouraging to formulate natural, safe products for young children to promote immunity and overall well-being so they can concentrate on learning,” said John Deaton, vice president of science and technology at Deerland. “Focusing on supporting a healthy microbiome will result in more robust and effective immunity as children get older.”

Deerland Probiotics & Enzymes, based in Kennesaw, Ga., specializes in developing science-backed solutions that benefit microbiome health, using probiotic, prebiotic and enzyme technology. The company offers a line of unique, clinically validated branded products, including DE111®, PreforPro®, ProHydrolase®, Solarplast®, Glutalytic® and Bifolac® probiotic strains. Deerland collaborates with customers to develop innovative and often proprietary solutions in the dietary supplement, food and beverage, sports nutrition, and companion animal markets. In addition to branded ingredients and customized formulations, Deerland offers full turnkey products for private label through its YourBrand® portfolio. The company’s manufacturing services include bulk blends, capsules, stick packs and tablets, as well as bottling and labeling. To contact Deerland Probiotics & Enzymes, call 800.697.8179 or visit www.deerland.com.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

The chief data and AI officer at Cedars-Sinai discusses the evolving role of AI in healthcare. While the first wave of AI focused on enhancing productivity, the second wave is expected to transform job roles and the workforce structure. This shift indicates a deeper integration of AI technology in healthcare operations.

  • 01First wave of AI increased productivity in healthcare.
  • 02Second wave aims to restructure job roles.
  • 03AI will deeply integrate into healthcare operations.

Jul 13, 2026

Automation adoption gap widens in US manufacturing as medtech presses ahead

Automation adoption gap widens in US manufacturing as medtech presses ahead

Automation in US manufacturing lags, with 80% of factories lacking automation tools. In contrast, medtech manufacturers are advancing with technologies like micro-molding and ultrasonic welding. This disparity highlights a growing gap in technology adoption across different sectors.

  • 0180% of US factories have no automation.
  • 02Medtech manufacturers are investing in automation technologies.
  • 03There's an increasing divide in technology adoption across industries.

Jul 12, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512